Taiko Pharmaceutical Co.,Ltd. (TYO:4574)
270.00
+1.00 (0.37%)
Aug 25, 2026, 3:30 PM JST
Taiko Pharmaceutical Revenue
Taiko Pharmaceutical had revenue of 1.72B JPY in the quarter ending June 30, 2026, with 36.29% growth. This brings the company's revenue in the last twelve months to 6.62B, up 13.30% year-over-year. In the year 2025, Taiko Pharmaceutical had annual revenue of 6.40B with 1.67% growth.
Revenue (ttm)
6.62B
Revenue Growth
+13.30%
P/S Ratio
2.05
Revenue / Employee
30.10M
Employees
220
Market Cap
13.58B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 6.40B | 105.00M | 1.67% |
| Dec 31, 2024 | 6.29B | 172.00M | 2.81% |
| Dec 31, 2023 | 6.12B | 1.08B | 21.43% |
| Dec 31, 2022 | 5.04B | -6.26B | -55.39% |
| Dec 31, 2021 | 11.30B | -11.16B | -49.68% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Pharma Foods International | 67.00B |
| Fuso Pharmaceutical Industries,Ltd. | 62.85B |
| Fuji Pharma | 60.11B |
| Daito Pharmaceutical | 50.65B |
| Nippon Chemiphar | 33.02B |
| Koa Shoji Holdings | 24.68B |
| Morishita Jintan | 12.82B |
| Mizuho Medy | 10.82B |